» Articles » PMID: 28870942

Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up

Overview
Journal Anticancer Res
Specialty Oncology
Date 2017 Sep 6
PMID 28870942
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with brain metastases (BRM) generally have a poor prognosis with infrequent long-term outcomes. Four patients treated by stereotactic radiosurgery (SRS) for BRM between 2000 and 2010 with a minimum follow-up of 10 years are described. The mean age was 43.5 years, and these individuals exhibited good performance status at the time of diagnosis of intracranial disease. BRM was solitary or multiple, and the primary malignant tumor originated from the thyroid gland, lung, mediastinum or large intestine. Progression of the original and secondary tumors subsequent to diagnosis and SRS was not observed. Radioimaging of the brain obtained 9 years later in one of the patients who was asymptomatic at follow-up revealed white matter changes; BRM in this individual was treated by tumor resection and cranial irradiation prior to SRS. We contend that extended longevity is not precluded when standard management of BRM is practiced in selected cases.

Citing Articles

Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement.

Nieder C, Dalhaug A, Mannsaker B In Vivo. 2022; 36(2):801-805.

PMID: 35241535 PMC: 8931931. DOI: 10.21873/invivo.12766.


Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement.

Nieder C, Dalhaug A, Pawinski A In Vivo. 2018; 33(1):229-232.

PMID: 30587628 PMC: 6364069. DOI: 10.21873/invivo.11464.


Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases.

Nieder C, Yobuta R, Mannsaker B In Vivo. 2018; 33(1):173-176.

PMID: 30587619 PMC: 6364059. DOI: 10.21873/invivo.11455.


Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases.

Rades D, Blanck O, Khoa M, VAN Thai P, Hung N, Dziggel L In Vivo. 2018; 32(2):381-384.

PMID: 29475924 PMC: 5905209. DOI: 10.21873/invivo.11249.